 HONG KONG and FLORHAM PARK, N.J., Sept. 20, 2021 GLOBE NEWSWIRE -- HUTCHMED China Limited HUTCHMED NasdaqAIM: HCM; HKEX: 13 today announces that it has initiated SURTORI-01, a Phase III study to evaluate the efficacy and safety of sur ufatinib SULANDA in China in combination with tori palimab compared with FOLFIRI to treat patients with advanced neuroendocrine carcinoma NEC who have progression of disease or intolerable toxicity after previous first-line chemotherapy. The first patient was dosed on September 18, 2021 in China. Toripalimab is marketed as TUOYI in China by Shanghai Junshi Biosciences Co., Ltd. Junshi Biosciences. 